The symptoms caused by benign prostatic hyperplasia , are associated with obstruction of the bladder outflow tract, which occurs as a result of the static obstruction due to an enlarged prostate, and dynamic obstruction, which depends on the smooth muscle tone of the prostate and bladder neck controlled sympathetic nervous system. By blocking smooth muscle alpha1 -adrenoceptors prostate and bladder neck, urinary terazosin helps normalize the patients with buy proviron. symptoms Reduction related , with terazosin application may be associated with a decrease in muscle tone caused by the blockade of alpha1-adrenergic receptors in the smooth muscle of the bladder neck and prostate. It is the expansion of arterioles and venules, reduces the total peripheral vascular resistance and venous return to the heart, resulting in a reduced pre- and afterload on the heart and blood pressure. Antihypertensive action Starting 15 min after oral administration (single dose). Duration of the antihypertensive action – 24 hours. The maximum effect in a single dose is achieved within 2-3 hours Resistant antihypertensive effect is reached after 6-8 weeks of therapy.. Little effect on cardiac output, renal perfusion and glomerular filtration rate. Prolonged use of terazosin does not usually cause the development of reflex tachycardia. Terazosin helps normalize lipid metabolism: decreases the concentration of cholesterol, triglycerides and lipoprotein and very low density in the blood, while increasing the amount of high density lipoproteins. The systematic use of terazosin is marked regression of left ventricular hypertrophy.
After oral terazosin is rapidly and almost completely absorbed from the gastrointestinal tract. Food does not affect the absorption. The buy proviron bioavailability of terazosin is 80-100%. For terazosin is not characteristic of the effect of “first pass”, so almost all of the dose of unchanged terazosin enters the systemic circulation. Maximum serum concentrations achieved within 1-2 hours after ingestion. Communication with plasma proteins is 90-94% and is independent of the concentration of terazosin in the blood plasma. Terazosin metabolized in the liver by hydrolysis, demethylation and dealkylation to form a 5 metabolites, one of which (piperazine derivative terazosin) a pharmacologically active. Approximately 60% of the dose appears through the gut (of which 20% – unchanged, the rest – in the form of metabolites), 40% – by the kidneys (of which 10% – unchanged). It is not known whether terazosin buy proviron is excreted in breast milk. The is 8 -13 hours. Terazosin clearance is reduced When liver failure. The use of terazosin in patients with impaired renal function requires careful monitoring of the patient’s condition. Limited pharmacokinetic study of low-dose (1 mg) showed no obvious differences terazosin pharmacokinetic parameters compared with patients with normal renal function. Indications
- Benign prostatic hyperplasia (symptomatic treatment).
- Hypertension (in combination therapy).
Hypersensitivity to terazosin, quinazolinyl other, and any of the components, other alpha-blockers; hypotension; tendency to orthostatic dysregulation, including a history; severe liver function; simultaneous application of inhibitors of phosphodiesterase-5 (PDE-5), including sildenafil, tadalafil and vardenafil; concomitant obstruction of the upper urinary tract; chronic urinary tract infections or bladder stones;decrease in the rate of outflow of urine; anuria; age of 18 years; lactose intolerance, lactase deficiency, glucose-galactose malabsorption, pregnancy and lactation.
Coronary heart disease buy proviron or other heart disease: pulmonary edema with aortic or mitral stenosis, heart failure with an increase in minute ejection, right ventricular failure caused by pulmonary embolism or exudative pericarditis, left ventricular failure with low pressure ventricular filling , cerebrovascular accident, hypertensive retinopathy grade III or IV, type 1 diabetes, liver dysfunction and mild to moderate severity; the simultaneous use of terazosin with thiazide diuretics or other antihypertensive agents; renal impairment, advanced age of 65 years.